NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 6 நாட்களுக்கு முன்இன்று 57 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Kaya Reports Q2 Revenue Up 21% to ₹65 Cr; Net Loss Narrows to ₹12.5 Cr
Kaya Limited released its media update for the quarter ended September 30, 2026, reporting revenue from operations of ₹65.0 crore, up 21% year-on-year compared to Q2 FY26. Net loss narrowed to ₹12.5 crore from ₹18.7 crore in the corresponding prior-year quarter. Growth was driven by a 22% increase in the Services business and 25% growth in the Skin segment. The company noted that bottom-line performance was impacted by GST 2.0 changes effective September 2025 restricting input tax credit availability.
உச்சம் நம்பிக்கை
என்ன மாறியதுKaya issued a media release detailing top-line acceleration (21% YoY) and narrowed net losses for the quarter ended September 30, 2026.
ஏன் இது முக்கியம்Demonstrates consistent top-line recovery in the domestic clinic and services business, though continuing losses and input tax credit restrictions remain operational headwinds.
Q2 Revenue from operations: ₹ 65.0 crsRevenue growth YoY: 21%Q2 Net Loss: ₹ (12.5) crsQ2 FY26 Net Loss: ₹ (18.7) crsQ2 வருவாய் vs TTM வருவாய்: ~29.3%
📅 குறுகிய காலம்The narrowing of losses alongside 21% revenue growth provides near-term operational relief, though overall profitability remains negative.
📈 நீண்ட காலம்Turnaround hinges on reaching sustainable operating profitability to service existing debt of ₹296 Cr and restore negative net worth after divestment of Middle East operations.
⚠ அபாய எச்சரிக்கைகள்
Persistent quarterly net losses
Negative net worth (₹-153 Cr) and elevated debt levels (₹296 Cr)
Adverse impact on margins due to restricted GST input tax credit
👀 கவனிக்க வேண்டியவை
Track whether sustained revenue growth can push operating profit into positive territory, and monitor balance sheet health given the negative net worth (₹-153 Cr as of latest financials).
Kaya Limited approved its unaudited standalone financial results for Q2 FY27 (quarter ended September 30, 2026), with the statutory auditor issuing an unmodified opinion but including an Emphasis of Matter regarding going concern due to negative net worth and working capital. The standalone balance sheet shows negative equity of ₹17,375.98 lakh (negative ₹173.76 crore) as of September 30, 2026. Additionally, the Board approved granting 4,80,000 ESOPs to an employee exceeding 1% of issued share capital and appointed Ms. Shuchi Pandya as an Independent Director for 5 years, both subject to postal ballot approval.
உச்சம் நம்பிக்கை
என்ன மாறியதுKaya reported its half-yearly financial position showing widening negative net worth, appointed a new Independent Director, and granted 4.80 lakh stock options requiring shareholder approval.
ஏன் இது முக்கியம்Persistent losses have expanded standalone negative net worth to ₹173.8 crore against a market cap of ₹456 crore, keeping the business reliant on promoter funding to meet obligations over the next 12 months.
📅 குறுகிய காலம்Market attention is likely to focus on the continued going concern observations by the statutory auditor and negative equity deterioration.
📈 நீண்ட காலம்Turnaround depends heavily on clinic-level rationalization, Indian market operational profitability, and sustained promoter backstopping.
⚠ அபாய எச்சரிக்கைகள்
Auditor emphasis of matter on going concern assumption
Negative net worth of ₹173.76 crore and negative working capital
Equity dilution from ESOP grant exceeding 1% of issued share capital
👀 கவனிக்க வேண்டியவை
Monitor the outcome of the postal ballot for the ESOP grant and director appointment, and track cash burn and promoter financial support commitments in upcoming quarters.
Kaya Allots 18.24 Lakh Shares via Preferential Issue to Raise ₹50 Crore
Kaya Limited has approved the allotment of 18,24,150 equity shares on a preferential basis at an issue price of ₹274.10 per share, raising approximately ₹50 crore (₹49,99,99,515). The allotment was made to two non-promoter investors: Axana Estates LLP (8,45,009 shares) and Plutus Investments India Private Limited (9,79,141 shares). This fundraise represents ~11.4% of the company's current market cap of ₹439 crore and infuses much-needed equity into a balance sheet with negative net worth (-₹153 crore) and ₹296 crore in debt. Post-allotment, the company's paid-up equity share capital increases to ₹17.01 crore across 1.70 crore shares.
உச்சம் நம்பிக்கை
என்ன மாறியதுKaya issued 18.24 lakh shares on a preferential basis, expanding its equity base and bringing ₹50 crore of fresh capital from two institutional non-promoter entities.
ஏன் இது முக்கியம்Given Kaya's negative net worth of ₹-153 crore and debt of ₹296 crore, a ₹50 crore equity injection represents ~22.5% of TTM revenue and provides critical liquidity support to absorb ongoing operational losses.
Fundraise Amount: ₹49,99,99,515Issue Price per Share: ₹274.10Shares Allotted: 18,24,150Fundraise vs Market Cap: ~11.4%Fundraise vs TTM Revenue: ~22.5%
📅 குறுகிய காலம்Eases short-term working capital and liquidity constraints, supporting the stock price around the preferential issue benchmark of ₹274.10.
📈 நீண்ட காலம்Helps rebuild eroded net worth, though structural recovery will depend on stopping persistent operational losses (-₹97 crore TTM net loss).
⚠ அபாய எச்சரிக்கைகள்
Equity dilution of ~10.7% for existing public shareholders.
Company continues to run negative operating margins (-10.5% TTM) and negative net worth.
👀 கவனிக்க வேண்டியவை
Track the deployment of the ₹50 crore proceeds toward balance sheet de-leveraging or working capital in upcoming quarterly updates, and monitor the subsequent reduction in negative net worth.
Kaya Receives In-Principle Approval for ₹50 Cr Preferential Equity Issue
Kaya Limited has received in-principle approval from BSE and NSE on October 19, 2026, for its proposed preferential issue. The company plans to issue 18,24,150 equity shares of face value ₹10 each at an issue price of ₹274.10 per share, raising approximately ₹50 crore (₹49,99,99,515). The allotment is to non-promoter investors Axana Estates LLP and Plutus Investments India Private Limited. The fundraise represents roughly 11.4% of Kaya's current market cap of ₹439 crore and is crucial given its negative net worth of ₹-153 crore and debt of ₹296 crore.
உச்சம் நம்பிக்கை
என்ன மாறியதுBSE and NSE have granted in-principle regulatory approvals for Kaya's ₹50 crore preferential share issue.
ஏன் இது முக்கியம்The capital infusion is vital for Kaya, which currently operates with negative net worth (₹-153 crore) and high debt (₹296 crore), offering immediate liquidity support.
Total fundraise value: Rs. 49,99,99,515Issue price per share: Rs. 274.10Number of shares: 18,24,150Fundraise vs Market Cap: ~11.4%
📅 குறுகிய காலம்Removes a key regulatory hurdle for the fundraise, enabling the company to proceed toward formal allotment and receipt of funds.
📈 நீண்ட காலம்Provides necessary equity capital to partially shore up a depleted balance sheet, though sustainable recovery depends on reversing operating losses.
⚠ அபாய எச்சரிக்கைகள்
Equity dilution for existing shareholders
Persistently negative operating profit margins and net losses
👀 கவனிக்க வேண்டியவை
Track the execution timeline for actual allotment, fund receipt, and management commentary on whether the proceeds will be directed toward debt reduction or operational turnaround.
Kaya Shareholders Approve Preferential Issue and Appoint Rishabh Mariwala as MD at EGM
Kaya Limited shareholders have approved all four resolutions at the Extraordinary General Meeting held on September 5, 2026, with over 99.99% voting in favour. Key approvals include the issuance of equity shares on a preferential basis and the appointment of Rishabh Mariwala as Managing Director for 5 years effective November 1, 2026. Harsh Mariwala will transition to Chairman and Non-Executive Director starting November 1, 2026, following the completion of his term as CMD. Additionally, shareholders sanctioned amendments to the Kaya Employee Stock Option Plan 2021.
உச்சம் நம்பிக்கை
என்ன மாறியதுShareholders formally approved a preferential share issue and the planned top-management leadership succession effective November 1, 2026.
ஏன் இது முக்கியம்Enables the company to execute planned capital raising to strengthen its balance sheet (net worth stood at Rs -153 Cr) and completes executive leadership succession to the next generation.
EGM Date: செப்டம்பர் 05, 2026Preferential Issue Approval %: 99.9999%MD Appointment Effective Date: நவம்பர் 01, 2026MD Term: 5 yearsTotal Shareholders on Record Date: 18146
📅 குறுகிய காலம்Administrative clarity achieved; focus shifts to final allotment filings and receipt of preferential equity funds.
📈 நீண்ட காலம்Leadership transition to Rishabh Mariwala sets the strategic direction for Kaya's clinic rationalisation and domestic business turnaround.
⚠ அபாய எச்சரிக்கைகள்
Dilution risk from preferential equity issuance
Execution risk regarding business turnaround amidst negative operating margins and negative net worth
👀 கவனிக்க வேண்டியவை
Track subsequent disclosures regarding the exact allotment details, issue price, and proceeds from the preferential equity issue, as well as operational strategy under the new Managing Director.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Kaya EGM Approves Preferential Issue & Appoints Rishabh Mariwala as MD from Nov 1, 2026
Kaya Limited concluded its Extraordinary General Meeting (EGM) on September 05, 2026, to vote on key corporate and leadership resolutions. Shareholders considered the appointment of Mr. Rishabh Mariwala as Managing Director for 5 years and the transition of Mr. Harsh Mariwala to Chairman and Non-Executive Director, both effective November 01, 2026. The meeting also transacted resolutions for the issuance of equity shares on a preferential basis and amendments to the Kaya ESOP 2021. Final voting tallies will be released following the scrutinizer's report.
உச்சம் நம்பிக்கை
என்ன மாறியதுKaya transacted EGM resolutions for succession in executive leadership and authorization of a preferential equity issue.
ஏன் இது முக்கியம்The MD transition signals generational management shift while the proposed preferential capital raise is critical for a company currently operating with a negative net worth of Rs -153 Cr.
MD Appointment Tenure: 5 consecutive yearsLeadership Effective Date: நவம்பர் 01, 2026EGM Date: செப்டம்பர் 05, 2026Company Net Worth (Financial Context): Rs -153 Cr
📅 குறுகிய காலம்Market focus will remain on the detailed terms and pricing of the preferential share issue once the scrutinizer's report is submitted.
📈 நீண்ட காலம்Rishabh Mariwala's appointment as MD comes amid operational restructuring to turnaround loss-making clinics and de-leverage the balance sheet.
⚠ அபாய எச்சரிக்கைகள்
Negative net worth of Rs -153 Cr and TTM net loss of Rs -97 Cr
Potential equity dilution from the proposed preferential issuance
Execution risk in competitive wellness and skin-care retail sector
👀 கவனிக்க வேண்டியவை
Track the upcoming disclosure of final voting results and detailed allotment specifics regarding the preferential issue size, price, and allottees.
₹50 Cr Preferential Issue to Non-Promoters; EGM Scheduled for Sept 05, 2026
Kaya Limited has announced a preferential issue of 18,24,150 equity shares to raise approximately ₹50 crore from non-promoter investors Axana Estates LLP and Plutus Investments India Private Limited. The shares are priced at ₹274.10 each, which is close to the current market price of ₹289.2. This capital infusion is critical for the company, which currently faces a negative net worth of -₹153 crore and a total debt of ₹296 crore. An Extraordinary General Meeting (EGM) is scheduled for September 05, 2026, to seek shareholder approval for this fundraise.
உச்சம் நம்பிக்கை
என்ன மாறியதுKaya is shifting from a period of divestment (Middle East business) to active capital raising, bringing in new non-promoter investors to strengthen its balance sheet.
ஏன் இது முக்கியம்With a TTM loss of ₹97 crore and negative net worth, this ₹50 crore infusion provides essential liquidity to support the company's India-focused consolidation strategy and potentially reduce its ₹296 crore debt burden.
Total Fundraise: ₹49.99 கோடிIssue Price per Share: ₹274.10Fundraise vs Market Cap: ~11.7%Total Debt: ₹296 கோடிNet Worth: ₹-153 கோடிTTM Net Profit: ₹-97 கோடி
📅 குறுகிய காலம்The stock may see interest due to the entry of new institutional-style investors (LLPs/Private Ltd) at a price near the current market value, providing a floor for the stock price.
📈 நீண்ட காலம்While the fundraise is a positive step for survival, the long-term outlook depends on the company's ability to turn around its operating margins (-10.5%) and successfully execute its India-centric clinic rationalization strategy.
⚠ அபாய எச்சரிக்கைகள்
Equity dilution
Persistent operating losses
Negative net worth
High debt-to-equity ratio
👀 கவனிக்க வேண்டியவை
Investors should monitor the EGM voting results on September 05 and the subsequent allotment timeline, as the company needs this capital to address its negative net worth and high debt levels.
Rs 50 Cr Preferential Issue at Rs 274.10/share to Axana Estates and Plutus Investments
Kaya Limited's board has approved a preferential issue of 18,24,150 equity shares to raise approximately Rs 50 crore. The issue price of Rs 274.10 is at a slight premium to the current market price of Rs 271.0. This capital infusion is critical for the company, which currently reports a negative net worth of Rs -153 crore and TTM losses of Rs 97 crore. The board also approved increasing the ESOP pool by 4,00,000 options to a total of 12,03,204 options.
உச்சம் நம்பிக்கை
என்ன மாறியதுKaya is initiating a fresh equity fundraise of Rs 50 Cr from two investors and expanding its employee stock option plan.
ஏன் இது முக்கியம்The fundraise is vital for solvency as the company has a negative net worth of Rs 153 Cr and high debt of Rs 296 Cr; the premium pricing suggests investor confidence despite recent losses.
Fundraise Amount: Rs 49.99 கோடிIssue Price: Rs 274.10Fundraise vs Market Cap: ~12.5%Post-issue stake (Axana Estates): 17.25%ESOP Pool Increase: 4,00,000 options
📅 குறுகிய காலம்The stock may see positive sentiment as the issue price is above the current market price and addresses immediate liquidity needs.
📈 நீண்ட காலம்While the capital helps repair the balance sheet, long-term value depends on reversing the negative operating margins (-10.5%) and achieving profitability post-Middle East divestment.
⚠ அபாய எச்சரிக்கைகள்
Equity dilution for existing shareholders
Persistent operational losses (TTM PAT of Rs -97 Cr)
Negative net worth of Rs -153 Cr
👀 கவனிக்க வேண்டியவை
Monitor the shareholder approval at the EGM on September 5, 2026, and watch for management commentary on whether these funds will be used to reduce the Rs 296 Cr debt or for working capital.
14% Revenue Growth in Q1 FY27; Net Loss Widens to ₹15.2 Cr
Kaya Limited reported a 14% YoY increase in revenue to ₹60.1 Cr for Q1 FY27, driven by double-digit growth across its clinic (16%) and product (16%) segments. However, the company's net loss widened slightly to ₹15.2 Cr from ₹14.2 Cr in the previous year's quarter. Management attributed the increased loss to the impact of GST 2.0 changes effective September 2025, which restricted input tax credit availability. The company continues to face financial stress with a negative net worth of ₹153 Cr as per the latest annual data.
உச்சம் நம்பிக்கை
என்ன மாறியதுKaya reported its Q1 FY27 results showing healthy top-line growth across all segments but a widening net loss due to regulatory tax changes.
ஏன் இது முக்கியம்While the brand shows growth momentum in services and products, the persistent losses and negative net worth (₹-153 Cr) remain significant structural risks for the business.
Revenue (Q1 FY27): ₹60.1 கோடிNet Loss (Q1 FY27): ₹15.2 கோடிRevenue vs TTM Revenue: ~27%Clinic Count: 82Skin Business Growth: 19%
📅 குறுகிய காலம்The market may view the 14% revenue growth as a positive sign of demand, but the widening loss and negative equity are likely to keep the stock price under pressure.
📈 நீண்ட காலம்The company needs a significant operational turnaround and capital infusion to address its negative net worth and high debt levels (₹296 Cr).
⚠ அபாய எச்சரிக்கைகள்
Negative net worth (₹-153 Cr)
Persistent net losses
Regulatory impact on margins (GST 2.0)
High debt-to-equity ratio
👀 கவனிக்க வேண்டியவை
Monitor whether the company can sustain its 14-16% revenue growth trajectory to eventually offset the margin pressure caused by GST 2.0 and its high fixed-cost clinic model.
Kaya Appoints Rishabh Mariwala as MD; Q1 Revenue Grows 14% to ₹60.1 Cr
Kaya Limited has announced a significant leadership transition, with Rishabh Mariwala appointed as Managing Director for a 5-year term starting November 1, 2026, as founder Harsh Mariwala moves to a Non-Executive Chairman role. For Q1 FY27, the company reported revenue of ₹60.14 crore, a 13.9% increase from ₹52.79 crore in the previous year's quarter. Despite revenue growth, the company remains under financial pressure with a negative net worth of ₹153 crore as of March 2026 and auditors continuing to flag 'going concern' risks. Notably, the board has deferred a planned fundraise through equity or debt until further notice.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has formalized a leadership succession plan and reported its Q1 results while simultaneously putting a planned capital raise on hold.
ஏன் இது முக்கியம்The transition to Rishabh Mariwala marks a major shift in management for the Marico-promoted entity, while the deferred fundraise and auditor warnings highlight ongoing liquidity and solvency challenges.
📅 குறுகிய காலம்The stock may see mixed sentiment as the market weighs the double-digit revenue growth against the delay in capital infusion and persistent losses.
📈 நீண்ட காலம்The structural shift to new leadership and the focus on the Indian market post-Middle East divestment are key, but long-term viability depends on reversing the negative net worth.
⚠ அபாய எச்சரிக்கைகள்
Negative net worth
Going concern assumption based on promoter support
Deferred fundraise
High debt-to-equity ratio
👀 கவனிக்க வேண்டியவை
Investors should monitor the leadership transition to the second generation and watch for any future announcements regarding the deferred fundraise, which is critical given the negative net worth.
Kaya Ltd: Rishabh Mariwala Appointed MD; Harsh Mariwala to Non-Executive Role from Nov 2026
Kaya Limited has announced a significant leadership transition with Rishabh Mariwala appointed as Managing Director for a 5-year term starting November 1, 2026. Current MD Harsh Mariwala will transition to a Non-Executive Chairman role. The company reported Q1 FY27 revenue of ₹60.14 Cr, a 13.9% increase YoY from ₹52.79 Cr. However, the board has deferred a planned fundraising initiative, which is critical given the company's negative net worth of ₹153 Cr and TTM losses of ₹97 Cr.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company initiated a formal leadership succession plan and reported quarterly results while delaying a previously planned capital raise.
ஏன் இது முக்கியம்The transition to the next generation of the promoter family is a major strategic milestone, but the deferral of fundraising is concerning given the company's fragile financial position and negative net worth.
📅 குறுகிய காலம்The market may react cautiously to the deferral of the fundraise despite the revenue growth, as the balance sheet remains under significant pressure.
📈 நீண்ட காலம்Succession provides clarity on leadership, but long-term viability depends on the new MD's ability to turn around the loss-making operations and repair the balance sheet.
⚠ அபாய எச்சரிக்கைகள்
Negative net worth
High debt-to-equity ratio
Deferral of fundraising
Going concern uncertainty noted by auditors
👀 கவனிக்க வேண்டியவை
Monitor the execution of the leadership transition and the timeline for the deferred fundraising, which is essential to address the negative net worth and high debt of ₹296 Cr.
Kaya Ltd Appoints Retail Veteran Brijesh Goyal as CFO Effective July 11, 2026
Kaya Limited has announced the appointment of Mr. Brijesh Goyal as its new Chief Financial Officer and Key Managerial Personnel, effective July 11, 2026. Mr. Goyal is a seasoned finance leader with over 30 years of experience, notably spending 14 years at Reliance Retail in various senior roles. His most recent position was Head of Finance at Enrich Hair & Skin Solutions, where he managed finance for a large-scale beauty and wellness platform. This appointment is expected to strengthen Kaya's financial governance and strategic decision-making as it navigates the competitive wellness retail space.
முக்கிய அம்சங்கள்
Mr. Brijesh Goyal appointed as CFO and Key Managerial Personnel effective July 11, 2026Brings over 30 years of experience in finance, P&L stewardship, and retail operationsExtensive 14-year background in senior finance leadership roles at Reliance Retail LimitedPreviously served as Head of Finance at Enrich Hair & Skin SolutionsAuthorized to determine materiality of events for stock exchange disclosures effective May 20, 2026
👀 கவனிக்க வேண்டியவை
Investors should view the addition of a retail veteran with Reliance Retail experience as a positive move for financial discipline. Monitor the company's strategic shifts and margin management once the transition is complete in mid-2026.
Kaya Q4 FY26 Revenue Up 2% to ₹55.8 Cr; Net Loss Widens to ₹27.1 Cr
Kaya Limited reported a marginal 2% YoY increase in consolidated revenue to ₹55.8 crore for Q4 FY26. While the clinic business grew by 7% and the product business by 21%, the company faced a significant net loss of ₹27.1 crore compared to a loss of ₹7.1 crore in the previous year. This loss was heavily impacted by a one-time impairment charge of ₹11.8 crore on property, plant, and equipment. Despite strong growth in specific service categories like Acne & Scars (+52%), the overall bottom line remains under significant pressure.
முக்கிய அம்சங்கள்
Consolidated revenue grew 2% YoY to ₹55.8 crore for the quarter ended March 31, 2026.Net loss widened significantly to ₹27.1 crore from ₹7.1 crore in Q4 FY25.Acne & Scars services saw a robust growth of 52%, while the product business grew by 21%.Results were impacted by a one-time impairment loss of ₹11.8 crore on fixed assets.Clinic business revenue registered a 7% growth, driven by advanced diagnostic tools and new technology.
👀 கவனிக்க வேண்டியவை
Investors should remain cautious as the company continues to report substantial losses and impairment charges despite growth in niche segments. Monitor the company's ability to translate operational growth into bottom-line profitability.
Kaya Ltd Q4 FY26 Results; Extends Rs 32.38 Cr Promoter Loans for 7 Years
Kaya Limited has approved its audited financial results for the quarter and year ended March 31, 2026, with an unmodified auditor's opinion. A significant development is the 7-year extension of loans totaling Rs 32.38 crores provided by directors Harsh Mariwala and Rajendra Mariwala (Rs 16.19 crores each). While this provides liquidity relief, the auditors included an 'Emphasis of Matter' regarding the company's ability to continue as a going concern, noting its reliance on continued promoter support. The company's financial health remains dependent on these internal funding arrangements and operational recovery.
முக்கிய அம்சங்கள்
Approved audited standalone and consolidated financial results for the fiscal year ended March 31, 2026.Extended repayment period for a Rs 16.19 crore loan from Director Harsh Mariwala by 7 years.Extended repayment period for a Rs 16.19 crore loan from Director Rajendra Mariwala by 7 years.Auditors highlighted an 'Emphasis of Matter' regarding the going concern assumption, citing dependence on promoter support.Total promoter loan extension of Rs 32.38 crores provides a significant long-term debt cushion.
👀 கவனிக்க வேண்டியவை
Investors should exercise caution as the auditor's 'going concern' note indicates underlying financial stress despite promoter backing. Monitor the company's ability to generate positive cash flows from operations to reduce its reliance on director-funded debt.
Kaya Appoints Brijesh Goyal as CFO (Designate); Arihant Dhariwal to Resign in July 2026
Kaya Limited has announced a planned leadership transition in its finance department. Mr. Arihant Dhariwal has resigned as Chief Financial Officer to pursue external opportunities and will remain in his post until July 10, 2026. To facilitate a smooth handover, the company has appointed Mr. Brijesh Goyal as CFO (Designate) effective April 13, 2026. Mr. Goyal, a Chartered Accountant with over 30 years of experience, previously held senior roles at Reliance Retail and Enrich Hair & Skin Solutions.
முக்கிய அம்சங்கள்
Mr. Arihant Dhariwal to step down as CFO effective close of business on July 10, 2026Mr. Brijesh Goyal appointed as CFO (Designate) effective April 13, 2026Mr. Goyal will formally assume the CFO role on July 11, 2026, subject to board approvalsIncoming CFO brings 30+ years of experience, including 14 years at Reliance RetailTransition period of approximately three months planned to ensure financial governance continuity
👀 கவனிக்க வேண்டியவை
Investors should view this as a routine leadership transition with a healthy overlap period. No immediate action is required, but monitor if the new CFO implements changes in financial strategy or cost structures post-July.
Kaya Shareholders Approve Change in Use of Preferential Issue Funds with 99.99% Majority
Kaya Limited has successfully passed a special resolution via postal ballot to change the objects clause regarding the utilization of funds raised through a previous preferential issue of equity shares. The resolution received overwhelming support, with 99.99% of the total 1,00,21,508 votes cast in favor. A total of 112 shareholders participated in the electronic voting process which concluded on March 2, 2026. This approval provides the company with the necessary mandate to redeploy capital as per its updated strategic requirements.
முக்கிய அம்சங்கள்
Special resolution passed to modify the objects clause for utilizing funds from a preferential equity issue.The resolution received 1,00,21,432 votes (99.99%) in favor and only 76 votes (0.01%) against.A total of 112 members participated in the remote e-voting process conducted between Feb 1 and March 2, 2026.Promoter and Promoter Group polled 77,61,555 votes, all of which were in favor of the resolution.Public non-institutions contributed 20,98,246 votes to the total count.
👀 கவனிக்க வேண்டியவை
Investors should monitor future disclosures to understand the specific new projects or operational areas where these funds will now be deployed. While the shareholder support is a positive sign for management, the impact on ROI will depend on the efficiency of the new capital allocation.
Kaya Q3 FY26 Revenue Up 3% to ₹60 Cr; Net Loss Widens to ₹36.2 Cr
Kaya Limited reported a modest 3% YoY revenue growth to ₹60 crore for Q3 FY26, driven by a 7% growth in its clinic business. However, the company faced a significant consolidated net loss of ₹36.2 crore, a sharp decline from the ₹3.5 crore profit reported in the same quarter last year. While specific service categories like Acne & Scars (+52%) and Products (+34%) showed strong momentum, the overall bottom line was heavily impacted. The widening losses despite marginal revenue growth suggest increased operational costs or significant one-time adjustments.
முக்கிய அம்சங்கள்
Consolidated revenue grew 3% YoY to ₹60.0 crore for the quarter.Net loss widened significantly to ₹36.2 crore compared to a profit of ₹3.5 crore in Q3 FY25.Acne & Scars services saw a robust 52% growth, aided by new technology adoption.Product business registered strong growth of 34% YoY, led by Nutraceuticals and Anti-Ageing segments.Clinic business revenue increased by 7% YoY and showed a 12% sequential improvement over Q2 FY26.
👀 கவனிக்க வேண்டியவை
Investors should exercise caution as the company has swung back into a significant loss despite marginal revenue growth. It is critical to monitor management's explanation for the bottom-line deterioration and the sustainability of high-growth niche segments.
Kaya Ltd to Reallocate Preferential Issue Funds for Working Capital Needs
Kaya Limited's Board has approved a variation in the utilization of proceeds from its preferential issue originally approved by members on July 22, 2025. While the funds were initially earmarked for growth and business expansion, the company now proposes to also deploy them toward meeting working capital requirements. This shift is intended to align capital allocation with current industry trends and ensure optimum utilization of funds. The proposed change is subject to the final approval of the company's shareholders.
முக்கிய அம்சங்கள்
Board approved variation in the objects of the preferential issue sanctioned on July 22, 2025Funds will now be utilized for working capital requirements in addition to growth and expansionDecision aims to improve operational efficiency and respond to competitive dynamicsThe reallocation of funds is subject to the upcoming approval of the shareholders
👀 கவனிக்க வேண்டியவை
Investors should monitor the shareholder resolution for details on the specific amount being diverted to working capital to assess if this indicates cash flow pressure or strategic flexibility.
Kaya Q3 FY26: Revenue Grows 3% YoY, Net Loss Widens Significantly to ₹35.5 Crore
Kaya Limited reported a marginal 3% year-on-year growth in standalone revenue to ₹60.03 crore for Q3 FY26. However, the net loss more than doubled to ₹35.55 crore compared to ₹15.40 crore in the same quarter last year, driven by a sharp rise in other expenses and an exceptional item of ₹5.19 crore. The company continues to face severe financial stress with a negative net worth and working capital position, relying heavily on promoter support to remain a going concern.
முக்கிய அம்சங்கள்
Revenue from operations increased to ₹6,003.66 Lakhs in Q3 FY26 from ₹5,835.06 Lakhs in Q3 FY25.Net loss widened to ₹3,554.87 Lakhs for the quarter, compared to a loss of ₹1,539.81 Lakhs in the previous year.Recognized an exceptional charge of ₹519.23 Lakhs related to the impact of new Labour Codes.Other expenses surged by 68% YoY to ₹3,976.48 Lakhs from ₹2,365.18 Lakhs.Auditors highlighted a 'going concern' risk as the company has negative net worth and working capital as of December 31, 2025.
👀 கவனிக்க வேண்டியவை
Investors should exercise extreme caution due to the company's widening losses and negative net worth. The stock remains high-risk, with survival currently dependent on continuous financial support from the promoter group.
Kaya Appoints Dhivya Ashok as COO for South & East Regions
Kaya Limited has appointed Ms. Dhivya Ashok as the Chief Operating Officer for its South and East regions, effective January 17, 2026. Ms. Ashok brings over 10 years of experience in scaling omni-channel, tech-enabled consumer businesses, including roles at CaratLane and Naturals Salon & Spa. Her expertise in the salon and spa industry, specifically building the Naturals@Home vertical, aligns well with Kaya's core business model. This appointment is expected to strengthen the company's regional leadership and operational execution in key Indian markets.
முக்கிய அம்சங்கள்
Appointment of Ms. Dhivya Ashok as COO - South & East effective January 17, 2026Over 10 years of experience in scaling consumer businesses across India and the USFormer Regional Business Head at CaratLane (A TATA Product) and Business Head at Naturals Salon & SpaPivotal experience as part of Uber's India Launch TeamStrengthens Senior Management Personnel (SMP) with specialized industry expertise
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive step towards professionalizing regional management; monitor if this leadership change leads to improved operational metrics in the South and East regions.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
